Public Research Library
Specialties:
Most Popular Reports:
- Laser Body Sculpting SmartLipo-Trends in Use
- Essure Permanent Birth Control
- Oral Contraceptives Market Evaluation
- Trends and Forecast of Dental Implant Cases
- Avastin and the AVADO Trial Survey
Newest Reports:
Drug Eluting Stents and Implantable Cardioverter Defibrillators: Changes in Referral Patterns
A Survey of One Hundred One Cardiologists
Deliverable: Survey with key findings.
Study Description:
|
Topic |
DES and ICD Referral Patterns |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Cardiologists |
|
Region |
United States Only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: 20 minutes Size: 101 respondents Fielding Dates: November 28, 2007 through December 10, 2007 |
Objectives:
To understand current practices and trends in referral patterns for implantable cardioverter defibrillators (ICDs) and drug eluting stents (DESs) among cardiologists in light of recent clinical data and product recalls/concerns. Specific objectives of this report include:
§ Examine protocols for ICD and DES referrals.
§ Assess changes in referral patterns and reasons for such changes.
§ Evaluate impact of remote monitoring reimbursement.
§ Understand recent changes in physician practices and perceptions.
§ Clarify near-term trends and drivers of change.
Companies and Products Mentioned in This Report:
§ Drug Eluting Stent Class Discussed in Aggregate
§ Implantable Cardioverter Defibrillators Discussed in Aggregate
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria
|
§ US-based cardiologists § Board-certified in specialty § 2 to 30 years of experience post-residency § Minimum of 75% professional time spent in clinical practice § Must refer patients to interventional cardiologists and electrophysiologists § Must see at least 2 ICD and 5 DES candidates per month |
Reports become free one year after the publication date.
 about us contact us |
 |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |